{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:11:14Z","timestamp":1787238674989,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03849-x","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T13:01:43Z","timestamp":1698238903000},"page":"957-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette\u2013Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-7459","authenticated-orcid":false,"given":"Yasar","family":"Pazir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-5058","authenticated-orcid":false,"given":"Abdullah","family":"Esmeray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-9396","authenticated-orcid":false,"given":"Ufuk","family":"Caglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-8288","authenticated-orcid":false,"given":"Akif","family":"Erbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-7458","authenticated-orcid":false,"given":"Faruk","family":"Ozgor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-1084","authenticated-orcid":false,"given":"Omer","family":"Sarilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-8143","authenticated-orcid":false,"given":"Fatih","family":"Akbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"issue":"6","key":"3849_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3849_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","volume":"17","author":"R Veeratterapillay","year":"2016","unstructured":"Veeratterapillay R et al (2016) High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep 17(9):68","journal-title":"Curr Urol Rep"},{"issue":"10061","key":"3849_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM et al (2016) Bladder cancer. Lancet 388(10061):2796\u20132810","journal-title":"Lancet"},{"issue":"1","key":"3849_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"3","key":"3849_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/02656736.2014.900194","volume":"30","author":"A Sousa","year":"2014","unstructured":"Sousa A et al (2014) A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia 30(3):166\u2013170","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"3849_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0305-7372(79)80043-2","volume":"6","author":"SB Field","year":"1979","unstructured":"Field SB, Bleehen NM (1979) Hyperthermia in the treatment of cancer. Cancer Treat Rev 6(2):63\u201394","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3849_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2307\/3577226","volume":"114","author":"LF Fajardo","year":"1988","unstructured":"Fajardo LF et al (1988) Hyperthermia inhibits angiogenesis. Radiat Res 114(2):297\u2013306","journal-title":"Radiat Res"},{"issue":"1","key":"3849_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/02656736.2020.1780328","volume":"37","author":"WP Tan","year":"2020","unstructured":"Tan WP et al (2020) Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Int J Hyperthermia 37(1):854\u2013860","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"3849_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/imt.10.1","volume":"2","author":"SF Shariat","year":"2010","unstructured":"Shariat SF et al (2010) Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy 2(3):381\u2013392","journal-title":"Immunotherapy"},{"issue":"1","key":"3849_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJ Lammers","year":"2011","unstructured":"Lammers RJ et al (2011) The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 60(1):81\u201393","journal-title":"Eur Urol"},{"issue":"10","key":"3849_CR11","doi-asserted-by":"publisher","first-page":"7453","DOI":"10.1007\/s00432-023-04688-0","volume":"149","author":"MA Arrabal Polo","year":"2023","unstructured":"Arrabal Polo MA et al (2023) Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA results of a prospective study. J Cancer Res Clin Oncol 149(10):7453\u20137459","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"3849_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","volume":"40","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos F et al (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol 40(4):999\u20131004","journal-title":"World J Urol"},{"issue":"5\u20136","key":"3849_CR13","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.5489\/cuaj.2708","volume":"9","author":"RG Ekin","year":"2015","unstructured":"Ekin RG et al (2015) Intravesical bacillus Calmette-Guerin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J 9(5\u20136):E278\u2013E283","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"3849_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4103\/UA.UA_139_20","volume":"13","author":"YB Thyavihally","year":"2021","unstructured":"Thyavihally YB et al (2021) Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer. Urol Ann 13(4):424\u2013430","journal-title":"Urol Ann"},{"key":"3849_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(19)33634-6","volume":"18","author":"F Chiancone","year":"2019","unstructured":"Chiancone F, Carrino M, Fedelini M et al (2019) Intravesical thermo-chemotherapy using the combined antineoplastic thermotherapy bladder recirculation system for BCG-failure patients: a single center experience. Eur Urol Suppl 18:e3248","journal-title":"Eur Urol Suppl"},{"issue":"5","key":"3849_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.urolonc.2020.01.002","volume":"38","author":"R Sood","year":"2020","unstructured":"Sood R et al (2020) A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer. Urol Oncol 38(5):433\u2013439","journal-title":"Urol Oncol"},{"key":"3849_CR17","unstructured":"NCI. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Accessed 14 sep 2020. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"issue":"12","key":"3849_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"TC Chua","year":"2009","unstructured":"Chua TC et al (2009) Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 135(12):1637\u20131645","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"3849_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.22017","volume":"104","author":"RS Gill","year":"2011","unstructured":"Gill RS et al (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 104(6):692\u2013698","journal-title":"J Surg Oncol"},{"issue":"20","key":"3849_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737\u20133743","journal-title":"J Clin Oncol"},{"key":"3849_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fonc.2020.00029","volume":"10","author":"K Liu","year":"2020","unstructured":"Liu K et al (2020) Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: a meta-analysis. Front Oncol 10:29","journal-title":"Front Oncol"},{"issue":"1","key":"3849_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","volume":"6","author":"JC Angulo","year":"2023","unstructured":"Angulo JC et al (2023) Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial. Eur Urol Oncol 6(1):58\u201366","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"3849_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","volume":"83","author":"WS Tan","year":"2022","unstructured":"Tan WS et al (2022) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol 83(6):497\u2013504","journal-title":"Eur Urol"},{"issue":"4","key":"3849_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/BLC-180191","volume":"4","author":"JJ de Jong","year":"2018","unstructured":"de Jong JJ et al (2018) Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer 4(4):395\u2013401","journal-title":"Bladder Cancer"},{"issue":"2","key":"3849_CR25","doi-asserted-by":"publisher","first-page":"62-e13","DOI":"10.1016\/j.urolonc.2021.07.019","volume":"40","author":"OM Pijpers","year":"2022","unstructured":"Pijpers OM et al (2022) Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol 40(2):62-e13-62-e20","journal-title":"Urol Oncol"},{"issue":"1","key":"3849_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1080\/02656736.2021.2002435","volume":"38","author":"L Doisy","year":"2021","unstructured":"Doisy L et al (2021) Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy. Int J Hyperthermia 38(1):1633\u20131638","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"3849_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170(3):777\u2013782","journal-title":"J Urol"},{"issue":"6","key":"3849_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69(6):1046\u20131052","journal-title":"Eur Urol"},{"key":"3849_CR29","doi-asserted-by":"publisher","first-page":"775527","DOI":"10.3389\/fsurg.2021.775527","volume":"8","author":"H Zhao","year":"2021","unstructured":"Zhao H et al (2021) Intravesical chemohyperthermia vs. bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. Front Surg 8:775527","journal-title":"Front Surg"},{"key":"3849_CR30","doi-asserted-by":"publisher","first-page":"1164932","DOI":"10.3389\/fonc.2023.1164932","volume":"13","author":"N Zeng","year":"2023","unstructured":"Zeng N et al (2023) Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a network meta-analysis. Front Oncol 13:1164932","journal-title":"Front Oncol"},{"key":"3849_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03765-0","author":"C You","year":"2023","unstructured":"You C et al (2023) Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-023-03765-0","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"3849_CR32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"A Ojea","year":"2007","unstructured":"Ojea A et al (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27\u00a0mg) versus very low-dose bacillus Calmette-Guerin (135\u00a0mg) versus mitomycin C. Eur Urol 52(5):1398\u20131406","journal-title":"Eur Urol"},{"issue":"6","key":"3849_CR33","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1097\/01.ju.0000158123.33273.f9","volume":"173","author":"D Michielsen","year":"2005","unstructured":"Michielsen D et al (2005) Mitomycin C and epirubicin: functional bladder damage in rats after repeat intravesical instillations. J Urol 173(6):2166\u20132170","journal-title":"J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03849-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:11:59Z","timestamp":1707394319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03849-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03849-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Haseki Training and Research Hospital (2022-214).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors give consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all patients included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}